Wednesday, March 6, 2013

Mantle Cell Lymphoma

*In Mantle cell lymphoma, Rituxan-Bendamustine beats R-CHOP
with progression  free survival of 69 months vs 31 months and with better toxicity profile
except for skin erythematous lesion often seen with Bendamustine.
Post a Comment